Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.05 USD | +3.74% | -0.97% | -45.44% |
May. 09 | Cantor Fitzgerald Adjusts DocGo Price Target to $5 From $11, Maintains Overweight Rating | MT |
May. 09 | Deutsche Bank Adjusts DocGo Price Target to $5 From $8.20, Maintains Buy Rating | MT |
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company is in a robust financial situation considering its net cash and margin position.
- The company shows low valuation levels, with an enterprise value at 0.34 times its sales.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-45.44% | 310M | - | ||
+1.23% | 3.14B | B- | ||
0.00% | 1.94B | - | ||
+20.20% | 1.8B | C | ||
+68.75% | 706M | D+ | ||
-14.59% | 443M | - | ||
-13.81% | 191M | - | ||
-16.75% | 129M | - | ||
+3.85% | 69.12M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- DCGO Stock
- Ratings DocGo Inc.